Matthew J. Byerly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew J. Byerly has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Augustus John Rush
Duke-NUS Medical School, Singapore
7 shared publications Paul A. Nakonezny
5 shared publicationsRobert Fisher
5 shared publicationsThomas Carmody
4 shared publicationsEmmeline Lescouflair
3 shared publicationsFemina Varghese
2 shared publications
Latest Publications
- 1 February 2009
- Published by Elsevier in Schizophrenia Research
- Vol. 107 (2-3) , 218-222
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study
- 1 February 2009
- Published by Elsevier in Schizophrenia Research
- Vol. 107 (2-3) , 218-222
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study
- 1 December 2007
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 27 (6) , 639-661
Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders
Hyperprolactinemia is increasingly studied as a frequent and potentially important consequence of antipsychotic medication treatment. Some individuals presenting with hyperprolactinemia remain asymptomatic, but others may exhibit a wide range of clinical symptoms resulting from either the direct effects of prolactin on body tissues (galactorrhea, gynecomastia) or endocrine-related secondary effects (sexual and reproductive dysfunction in the short term, and possibly the risk of tumorigenesis and osteoporosis in the longer term). Short-term side effects may negatively impact medication compliance, and long-term effects have the potential for serious health consequences. Antipsychotic medications have differing propensities to cause prolactin elevation. The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. A comprehensive overview of antipsychotics and hyperprolactinemia is presented together with a review of emerging evidence about the short- and long-term health risks of hyperprolactinemia.
- 1 December 2007
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 27 (6) , 639-661
Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders
Hyperprolactinemia is increasingly studied as a frequent and potentially important consequence of antipsychotic medication treatment. Some individuals presenting with hyperprolactinemia remain asymptomatic, but others may exhibit a wide range of clinical symptoms resulting from either the direct effects of prolactin on body tissues (galactorrhea, gynecomastia) or endocrine-related secondary effects (sexual and reproductive dysfunction in the short term, and possibly the risk of tumorigenesis and osteoporosis in the longer term). Short-term side effects may negatively impact medication compliance, and long-term effects have the potential for serious health consequences. Antipsychotic medications have differing propensities to cause prolactin elevation. The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. A comprehensive overview of antipsychotics and hyperprolactinemia is presented together with a review of emerging evidence about the short- and long-term health risks of hyperprolactinemia.
- 1 September 2007
- Published by Elsevier in Psychiatric Clinics of North America
- Vol. 30 (3) , 437-452
Antipsychotic Medication Adherence in Schizophrenia
- 1 September 2007
- Published by Elsevier in Psychiatric Clinics of North America
- Vol. 30 (3) , 437-452
Antipsychotic Medication Adherence in Schizophrenia
- 1 September 2006
- Published by Elsevier in Schizophrenia Research
- Vol. 86 (1-3) , 244-250
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine
- 1 September 2006
- Published by Elsevier in Schizophrenia Research
- Vol. 86 (1-3) , 244-250
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine
- 1 January 2006
- Published by Elsevier in Schizophrenia Research
- Vol. 81 (2-3) , 311-316
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder
- 1 January 2006
- Published by Elsevier in Schizophrenia Research
- Vol. 81 (2-3) , 311-316
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder
- 15 August 2005
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 66 (08) , 997-1001
A Trial of Compliance Therapy in Outpatients With Schizophrenia or Schizoaffective Disorder
To evaluate the efficacy of compliance therapy when delivered to outpatients with schizophrenia or schizoaffective disorder. Thirty patients with schizophrenia or schizoaffective disorder (DSM-IV criteria) were recruited from urban psychiatric outpatient clinics in an open trial of compliance therapy. Compliance therapy is a cognitive/psychoeducational approach consisting of 4 to 6 sessions lasting 30 to 60 minutes each. The primary outcome was electronically measured antipsychotic medication adherence. Adherence data were analyzed for effects during an initial treatment period (month -1 to month +1) and a subsequent 5-month follow-up period. Secondary outcome measures included clinician and patient ratings of adherence, symptoms, insight, and attitudes to medication treatment. Data were collected from August 2001 to January 2004. Compliance therapy was not associated with improvements in antipsychotic medication adherence. Patient ratings of adherence improved during the month -1 to month +1 period, but not in the subsequent 5-month follow-up. A diagnosis of schizoaffective disorder was associated with poorer adherence than was a diagnosis of schizophrenia during the month -1 to month +1 period. A higher degree of insight at baseline (end of month -1) was associated with greater adherence in the 5-month follow-up period. Symptoms, insight, and attitudes to medication treatment did not change significantly during the study. In this uncontrolled trial, outpatients with schizophrenia or schizoaffective disorder did not benefit from compliance therapy.
- 15 August 2005
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 66 (08) , 997-1001
A Trial of Compliance Therapy in Outpatients With Schizophrenia or Schizoaffective Disorder
To evaluate the efficacy of compliance therapy when delivered to outpatients with schizophrenia or schizoaffective disorder. Thirty patients with schizophrenia or schizoaffective disorder (DSM-IV criteria) were recruited from urban psychiatric outpatient clinics in an open trial of compliance therapy. Compliance therapy is a cognitive/psychoeducational approach consisting of 4 to 6 sessions lasting 30 to 60 minutes each. The primary outcome was electronically measured antipsychotic medication adherence. Adherence data were analyzed for effects during an initial treatment period (month -1 to month +1) and a subsequent 5-month follow-up period. Secondary outcome measures included clinician and patient ratings of adherence, symptoms, insight, and attitudes to medication treatment. Data were collected from August 2001 to January 2004. Compliance therapy was not associated with improvements in antipsychotic medication adherence. Patient ratings of adherence improved during the month -1 to month +1 period, but not in the subsequent 5-month follow-up. A diagnosis of schizoaffective disorder was associated with poorer adherence than was a diagnosis of schizophrenia during the month -1 to month +1 period. A higher degree of insight at baseline (end of month -1) was associated with greater adherence in the 5-month follow-up period. Symptoms, insight, and attitudes to medication treatment did not change significantly during the study. In this uncontrolled trial, outpatients with schizophrenia or schizoaffective disorder did not benefit from compliance therapy.
- 1 February 2005
- Published by Elsevier in Psychiatry Research
- Vol. 133 (2-3) , 129-133
A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia
- 1 February 2005
- Published by Elsevier in Psychiatry Research
- Vol. 133 (2-3) , 129-133
A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia
- 1 October 2004
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- Vol. 30 (5) , 325-332
An Open-Label Trial of Quetiapine for Antipsychotic-Induced Sexual Dysfunction
This study evaluated the effect of switching outpatients with schizophrenia and antipsychotic-induced sexual dysfunction to open-label quetiapine treatment. Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Eight patients with at least moderately severe antipsychotic-induced sexual dysfunction (N = 7 taking risperidone, 4–6 mg/d; N = 1 taking haloperidol, 10 mg/d) were evaluated prospectively after they switched to 6 weeks of quetiapine treatment. The assessments that we used included evaluations of sexual functioning ( Arizona Sexual Experience Scale [ASEX]; McGahuey et al., 2000 McGahuey, C. C. , Gelenberg, A. A. , Laukes, C. C. , Moreno, F. F. , Delgado, P. P. , McKnight, K. K. and Manber, R. 2000. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. Journal of Sex & Marital Therapy, 26: 25–40. [Taylor & Francis Online], [Web of Science ®] , [Google Scholar] ), psychopathology (Positive and Negative Syndrome Scale [PANSS]; Kay, Fiszbeinm, & Opler, 1997), adverse events, and plasma prolactin levels. Quetiapine was associated with clinically and statistically significant improvement in ASEX total scores (p = 0.008) and significantly decreased PANSS total scores (p = 0.03). Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine appears to offer an option to reduce antipsychotic-induced sexual dysfunction for outpatients with schizophrenia.
- 1 October 2004
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- Vol. 30 (5) , 325-332
An Open-Label Trial of Quetiapine for Antipsychotic-Induced Sexual Dysfunction
This study evaluated the effect of switching outpatients with schizophrenia and antipsychotic-induced sexual dysfunction to open-label quetiapine treatment. Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Eight patients with at least moderately severe antipsychotic-induced sexual dysfunction (N = 7 taking risperidone, 4–6 mg/d; N = 1 taking haloperidol, 10 mg/d) were evaluated prospectively after they switched to 6 weeks of quetiapine treatment. The assessments that we used included evaluations of sexual functioning ( Arizona Sexual Experience Scale [ASEX]; McGahuey et al., 2000 McGahuey, C. C. , Gelenberg, A. A. , Laukes, C. C. , Moreno, F. F. , Delgado, P. P. , McKnight, K. K. and Manber, R. 2000. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. Journal of Sex & Marital Therapy, 26: 25–40. [Taylor & Francis Online], [Web of Science ®] , [Google Scholar] ), psychopathology (Positive and Negative Syndrome Scale [PANSS]; Kay, Fiszbeinm, & Opler, 1997), adverse events, and plasma prolactin levels. Quetiapine was associated with clinically and statistically significant improvement in ASEX total scores (p = 0.008) and significantly decreased PANSS total scores (p = 0.03). Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine appears to offer an option to reduce antipsychotic-induced sexual dysfunction for outpatients with schizophrenia.